Retinal Hyperspectral Imaging in Neurodegenerative Diseases

What this Trial Is About

Researchers are studying the use of hyperspectral retinal imaging, a safe and non-invasive eye scan, to detect signs of dementia and other neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Lewy Body dementia, vascular dementia, and Niemann-Pick disease. This imaging method captures detailed pictures of the retina using different colors of light, which can reveal changes linked to the buildup of amyloid beta protein and other disease markers in the eye and brain. The goal is to develop a quick, affordable test to help detect and monitor these diseases early and assess treatment effects. Participants will have their retinas imaged using specialized hyperspectral cameras, including the Metabolic Hyperspectral Retinal Camera and a prototype camera developed by researchers at the Centre for Eye Research Australia. These cameras take detailed images across many wavelengths of light in less than a second, minimizing discomfort and eye movement effects. The imaging is done without pupil dilation in some cases and provides a wide view of the retina. This study does not involve treatments but focuses on evaluating the diagnostic potential of the imaging technology. During the study visit, participants will undergo the retinal imaging procedure and provide baseline data for analysis. Researchers will assess the ability of hyperspectral retinal imaging to classify different neurodegenerative diseases compared to existing diagnostic methods. Participants need to be willing to attend the study site and be accompanied by a friend or family member. The study includes monitoring for image quality and participant safety throughout. The primary outcome is the diagnostic classification of neurodegenerative diseases from the imaging data collected during the study visit.

Retinal Hyperspectral Imaging in Neurodegenerative Diseases